Evaluation of Crofelemer in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Patients

  title={Evaluation of Crofelemer in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Patients},
  author={Allen Wayne Mangel and Pravin R. Chaturvedi},
  pages={180 - 186}
Background: Crofelemer improves bowel function in several conditions characterized by states of prominent secretory diarrhea. Aim: This double-blind, randomized, placebo-controlled trial evaluated the effects of 3 dose levels of crofelemer in patients with diarrhea-predominant irritable bowel syndrome (D-IBS). Methods: Male and female patients were randomly assigned to receive crofelemer 125, 250 or 500 mg or placebo twice daily for 12 weeks. The primary efficacy measure was a responder for… 

Tables from this paper

Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome
Crofelemer did not significantly improve abdominal pain over placebo by the primary endpoint, however, it did based on the FDA abdominal pain monthly responder endpoint, which suggests that croFelemer may have a role in the treatment of abdominal pain associated with IBS-D.
Emerging drug for diarrhea predominant irritable bowel syndrome
Introduction: Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders with a 9 – 23% prevalence estimated in the general population. Patients can be subdivided into those
Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome
Eluxadoline showed a low rate of constipation development in IBS patients in comparison with known effects of other opioid receptor modulators, and its efficacy over placebo has been demonstrated in short- and long-term clinical studies in humans.
Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea
This review aimed to summarize the current and recent pharmacological treatment options in IBS-D, targeting the predominant gastrointestinal symptoms, and proposed a pharmacologicaltreatment algorithm which healthcare professionals could use when treating individual patients with IBS.
Asimadoline in the treatment of irritable bowel syndrome
In a prospectively defined, clinically relevant patient subgroup, asimadoline shows efficacy in the treatment of D-IBS, and the reader will gain an appreciation of kappa-opioid agonists as IBS treatments.
Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions
Interventions that may be considered in the management of patients with IBS with diarrhea (IBS-D) include dietary and lifestyle modification, which are generally used as first-line therapy, and psychological therapies, which may improve IBS symptoms.
Treatment of irritable bowel syndrome: sex and gender specific aspects.
There appears to be a greater clinical response to serotonergic agents developed for IBS in women compared to men, and there is an absence of drugs licensed specifically for the treatment of IBS.
Recent advances in pharmacological treatment of irritable bowel syndrome.
This article reviews the literature from January 2008 to July 2013 on the subject of IBS peripherally acting pharmacological treatment and categorizes drugs according to their administration for IBS-C, Ibs-D or abdominal pain predominant IBS.
Pharmacologic and Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome
There is persuasive evidence to suggest that selected antispasmodics and antidepressants are of benefit for the treatment of abdominal pain in IBS patients, and several emerging therapies with novel mechanisms of action are in development.
Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview
The pathophysiology of IBS remains elusive although potential causes have been suggested, such as a deranged brain-gut signaling, hypersensitivity of visceral sensory afferent fibers, bacterial gastroenteritis, small intestinal bacterial overgrowth, genetic alterations and food sensitivity.


Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome
These results in women with diarrhea-predominant IBS demonstrate that alosetron significantly improves health-related quality of life.
Review article: irritable bowel syndrome
Irritable bowel syndrome is the most common disease diagnosed by gastroenterologists and affects about 20% of all people at any one time; the illness has a large economic impact on health‐care utilization and absenteeism.
AGA technical review on irritable bowel syndrome.
Psychosocial factors, although not part of IBS per se, have an important role in modulating the illness experience and its clinical outcome.
The Clinical and Economic Burden of Irritable Bowel Syndrome
The need for a multidimensional approach to this illness to establish appropriate patient management strategies and reduce the economic burden of IBS to the patient, employer, and healthcare system is demonstrated.
A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico
SP-303 was effective in shortening the duration of travelers' diarrhea by 21%.
A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS
Results suggest that SP-303 may be effective in reducing stool weight and frequency in patients with AIDS and diarrhea.
Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation
Background  Analyses of a trial in constipated patients indicated that lubiprostone may be an effective treatment for irritable bowel syndrome with constipation.
Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome
A novel electronic data collection system that ensures the reliability and security of data entry was used in irritable bowel syndrome efficacy studies.